Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

[1]  C. Langer,et al.  Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. , 2021, JAMA oncology.

[2]  Diane D. Liu,et al.  Stereotactic Radiosurgery versus Whole-brain Radiation Therapy for Patients with 4-15 Brain Metastases: A Phase III Randomized Controlled Trial , 2020 .

[3]  J. Desai,et al.  KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. , 2020, The New England journal of medicine.

[4]  P. Brown,et al.  Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Magné,et al.  Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status , 2020, Journal for ImmunoTherapy of Cancer.

[6]  M. Ahluwalia,et al.  Current approaches to the management of brain metastases , 2020, Nature Reviews Clinical Oncology.

[7]  G. Barnett,et al.  The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis. , 2019, Neuro-oncology.

[8]  J. Wynne,et al.  Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation , 2018, Front. Oncol..

[9]  M. Mehta,et al.  Recent advances in managing brain metastasis , 2018, F1000Research.

[10]  R. Herbst,et al.  Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. , 2018 .

[11]  Soo Young Park,et al.  Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer , 2018, PloS one.

[12]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[13]  anonymous.  In Review , 2018 .

[14]  L. Crinò,et al.  P1.01-053 Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain Metastases , 2017 .

[15]  N. Girard,et al.  OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) , 2017 .

[16]  A. Akabane,et al.  A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. , 2017, International journal of radiation oncology, biology, physics.

[17]  G. Barnett,et al.  Three or More Courses of Stereotactic Radiosurgery for Patients with Multiply Recurrent Brain Metastases , 2017, Neurosurgery.

[18]  P. Brown,et al.  Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.

[19]  J. H. Kim,et al.  Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review , 2017, Oncotarget.

[20]  N. Chen,et al.  KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma , 2017, Cancer Immunology, Immunotherapy.

[21]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[22]  R. Salgia,et al.  Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. , 2016, JAMA oncology.

[23]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[24]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[25]  B. Chan,et al.  Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. , 2015, Translational lung cancer research.

[26]  Satoshi Suzuki,et al.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. , 2014, The Lancet. Oncology.

[27]  F. Hirsch,et al.  Contributions of KRAS and RAL in Non–Small-Cell Lung Cancer Growth and Progression , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.